Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy

Katherine A Skorupski, C. O. Rodriguez, E. L. Krick, C. A. Clifford, R. Ward, Michael S Kent

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Histiocytic sarcoma (HS) is associated with a poor prognosis owing to the presence of metastasis at the time of diagnosis in most dogs. Improved outcome has been reported in several dogs with localized HS following local therapy, however, distant metastasis occurs in 70-91% of dogs suggesting that adjuvant systemic therapy is necessary. The purpose of this retrospective study was to describe clinical characteristics and outcome in dogs with localized HS treated with aggressive local therapy plus adjuvant CCNU chemotherapy. Data from 16 dogs were evaluated. The median disease-free interval was 243 days. Two dogs had local recurrence and eight dogs developed metastatic disease with a median time to relapse of 201 days in these 10 dogs. The median survival time for all 16 dogs was 568 days. These results support the recommendation for aggressive local therapy combined with adjuvant CCNU chemotherapy in dogs with localized HS.

Original languageEnglish (US)
Pages (from-to)139-144
Number of pages6
JournalVeterinary and Comparative Oncology
Volume7
Issue number2
DOIs
StatePublished - 2009

Fingerprint

Histiocytic Sarcoma
Lomustine
sarcoma
adjuvants
Dogs
therapeutics
dogs
Therapeutics
Adjuvant Chemotherapy
metastasis
drug therapy
Neoplasm Metastasis
Recurrence
relapse
retrospective studies
prognosis
Retrospective Studies

Keywords

  • Chemotherapy
  • Metastasis
  • Oncology
  • Pathology
  • Radiation oncology

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy. / Skorupski, Katherine A; Rodriguez, C. O.; Krick, E. L.; Clifford, C. A.; Ward, R.; Kent, Michael S.

In: Veterinary and Comparative Oncology, Vol. 7, No. 2, 2009, p. 139-144.

Research output: Contribution to journalArticle

@article{40d4d78ed9c4463c9322023b7ed8c4e2,
title = "Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy",
abstract = "Histiocytic sarcoma (HS) is associated with a poor prognosis owing to the presence of metastasis at the time of diagnosis in most dogs. Improved outcome has been reported in several dogs with localized HS following local therapy, however, distant metastasis occurs in 70-91{\%} of dogs suggesting that adjuvant systemic therapy is necessary. The purpose of this retrospective study was to describe clinical characteristics and outcome in dogs with localized HS treated with aggressive local therapy plus adjuvant CCNU chemotherapy. Data from 16 dogs were evaluated. The median disease-free interval was 243 days. Two dogs had local recurrence and eight dogs developed metastatic disease with a median time to relapse of 201 days in these 10 dogs. The median survival time for all 16 dogs was 568 days. These results support the recommendation for aggressive local therapy combined with adjuvant CCNU chemotherapy in dogs with localized HS.",
keywords = "Chemotherapy, Metastasis, Oncology, Pathology, Radiation oncology",
author = "Skorupski, {Katherine A} and Rodriguez, {C. O.} and Krick, {E. L.} and Clifford, {C. A.} and R. Ward and Kent, {Michael S}",
year = "2009",
doi = "10.1111/j.1476-5829.2009.00186.x",
language = "English (US)",
volume = "7",
pages = "139--144",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5829",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy

AU - Skorupski, Katherine A

AU - Rodriguez, C. O.

AU - Krick, E. L.

AU - Clifford, C. A.

AU - Ward, R.

AU - Kent, Michael S

PY - 2009

Y1 - 2009

N2 - Histiocytic sarcoma (HS) is associated with a poor prognosis owing to the presence of metastasis at the time of diagnosis in most dogs. Improved outcome has been reported in several dogs with localized HS following local therapy, however, distant metastasis occurs in 70-91% of dogs suggesting that adjuvant systemic therapy is necessary. The purpose of this retrospective study was to describe clinical characteristics and outcome in dogs with localized HS treated with aggressive local therapy plus adjuvant CCNU chemotherapy. Data from 16 dogs were evaluated. The median disease-free interval was 243 days. Two dogs had local recurrence and eight dogs developed metastatic disease with a median time to relapse of 201 days in these 10 dogs. The median survival time for all 16 dogs was 568 days. These results support the recommendation for aggressive local therapy combined with adjuvant CCNU chemotherapy in dogs with localized HS.

AB - Histiocytic sarcoma (HS) is associated with a poor prognosis owing to the presence of metastasis at the time of diagnosis in most dogs. Improved outcome has been reported in several dogs with localized HS following local therapy, however, distant metastasis occurs in 70-91% of dogs suggesting that adjuvant systemic therapy is necessary. The purpose of this retrospective study was to describe clinical characteristics and outcome in dogs with localized HS treated with aggressive local therapy plus adjuvant CCNU chemotherapy. Data from 16 dogs were evaluated. The median disease-free interval was 243 days. Two dogs had local recurrence and eight dogs developed metastatic disease with a median time to relapse of 201 days in these 10 dogs. The median survival time for all 16 dogs was 568 days. These results support the recommendation for aggressive local therapy combined with adjuvant CCNU chemotherapy in dogs with localized HS.

KW - Chemotherapy

KW - Metastasis

KW - Oncology

KW - Pathology

KW - Radiation oncology

UR - http://www.scopus.com/inward/record.url?scp=65749101153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65749101153&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5829.2009.00186.x

DO - 10.1111/j.1476-5829.2009.00186.x

M3 - Article

C2 - 19453368

AN - SCOPUS:65749101153

VL - 7

SP - 139

EP - 144

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5829

IS - 2

ER -